Zenas BioPharma, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsZenas BioPharma is a clinical-stage biopharmaceutical company developing obexelimab, a bifunctional monoclonal antibody for autoimmune diseases, with a BLA accepted by the FDA for IgG4-RD.
What they do
Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on immunology and inflammation (I&I). Its lead candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit B-cell activity without depleting cells. The company is developing obexelimab for IgG4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS), and systemic lupus erythematosus (SLE). It also has an early-stage oral IL-17A/AF inhibitor, ZB021, in Phase 1 trials.
Revenue drivers
- Obexelimab (IgG4-RD) — Lead product candidate; BLA submitted and accepted by FDA with PDUFA date May 27, 2027; no commercial revenue yet.
- Obexelimab (RMS and SLE) — Phase 2 trials ongoing or reported; potential future revenue but not yet approved.
- Partnered rights (BMS) — Bristol Myers Squibb holds exclusive rights in Japan, South Korea, Taiwan, Singapore, Hong Kong, and Australia; BMS submitted an MAA to Japan's PMDA.
Recent performance
For the quarter ended June 30, 2026, Zenas reported $1.0M in revenue, compared to $0.0M in the year-ago quarter. Net loss for the first half of 2026 was not provided in the excerpts, but full-year 2025 net loss was $377.7M with a loss per share of $8.44. Cash, cash equivalents, and investments totaled $673.9M as of June 30, 2026, versus $196.6M in cash and equivalents on the balance sheet at that date (excluding investments). The company's operating cash flow for 2025 was -$172.3M.
Strategy
Zenas is building an I&I franchise around obexelimab, leveraging positive Phase 3 INDIGO data to file for regulatory approval in the U.S. and Europe. It plans to expand into new indications, including SLE and RMS, based on Phase 2 results. The company is also developing a prefilled pen for obexelimab to improve patient convenience. Management aims to become a fully integrated global development and commercial-stage biopharmaceutical company.
Risks
- Regulatory approval risk — FDA acceptance does not guarantee approval; PDUFA date set for May 27, 2027, but the BLA could face delays or rejection.
- Clinical trial risk — Phase 2 SLE trial (SunStone) topline results expected in Q4 2026; failure would delay or prevent Phase 3 initiation.
- Commercial execution risk — The company has no commercial product and must build sales and manufacturing capabilities ahead of a potential 2027 launch.
- Financial sustainability risk — Net losses are large and growing ($377.7M in 2025); operating cash flow is negative, so future funding may be needed.
Outlook
Management expects to report topline results from the SunStone Phase 2 SLE trial in Q4 2026, and initial Phase 1 data for ZB021 by year-end. It intends to submit an MAA to the EMA for obexelimab in IgG4-RD in the second half of 2026. Based on SunStone outcomes, a Phase 3 program in SLE could start in the first half of 2027. The company is preparing for potential commercialization of obexelimab, with a PDUFA action date of May 27, 2027.